arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

RELMADA THERAPEUTICS, INC.

RLMD

$3.77 ▼ -0.48 (-11.29%) at close

15 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

RELMADA THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $148.8M

Dividend Yield —

Revenue Growth —

Op. Margin None

ROIC -54.0% ↗

FCF / Share $-1.16 ↗

Trailing P/E —

Price / Book 3.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

15-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-57.39M

↑ +28.3% —

FCF / Share Free cash flow per share

$-1.16

↑ +32.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Jun 30, 2019 10-K ↗	FY 2017 Jun 30, 2018 10-K ↗	FY 2016 Jun 30, 2017 10-K ↗	FY 2015 Jun 30, 2016 10-K ↗	FY 2014 Jun 30, 2015 10-K ↗	FY 2013 Jun 30, 2014 10-K ↗	FY 2012 Aug 31, 2012 10-K ↗	FY 2011 Aug 31, 2011 10-K ↗
EPS Growth YoY (%)	45.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	19.2% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	38.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	26.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	28.3% Excellent ↑ Excellent Improving Year-over-year change in net income	19.0% Good ↑ Good Improving Year-over-year change in net income	37.1% Excellent ↑ Excellent Improving Year-over-year change in net income	-24.9% Weak ↑ Weak Improving Year-over-year change in net income	-111.5% Weak ↑ Weak Improving Year-over-year change in net income	-296.2% Weak ↓ Weak Declining Year-over-year change in net income	13.4% Fair ↑ Fair Improving Year-over-year change in net income	-93.3% Weak ↓ Weak Declining Year-over-year change in net income	-42.5% Weak ↓ Weak Declining Year-over-year change in net income	-111.3% Weak ↑ Weak Improving Year-over-year change in net income	85.7% Excellent ↑ Excellent Improving Year-over-year change in net income	-4.7% Weak Weak Year-over-year change in net income	-164784.7% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	32.4% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	0.0% Caution ↓ Caution Declining Year-over-year change in free cash flow	51.0% Excellent Excellent Year-over-year change in free cash flow	33.1% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Jun 30, 2019 10-K ↗	FY 2017 Jun 30, 2018 10-K ↗	FY 2016 Jun 30, 2017 10-K ↗	FY 2015 Jun 30, 2016 10-K ↗	FY 2014 Jun 30, 2015 10-K ↗	FY 2013 Jun 30, 2014 10-K ↗	FY 2012 Aug 31, 2012 10-K ↗	FY 2011 Aug 31, 2011 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	—	—	—	—	—	—	—	—	-151.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1112%)	—
Profit Margin (%) (%)	—	—	—	—	—	—	—	—	—	—	—	—	—	-151.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1365%)	—
FCF Margin (%) (%)	—	—	—	—	—	—	—	—	—	—	—	—	—	-95.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.80x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.65x Weak → Weak Stable Free cash flow relative to reported net income Optimal: > 1x	0.52x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak → Weak Stable Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.47x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.61x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.67x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.03x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	4.42x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.11x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.63x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Jun 30, 2019 10-K ↗	FY 2017 Jun 30, 2018 10-K ↗	FY 2016 Jun 30, 2017 10-K ↗	FY 2015 Jun 30, 2016 10-K ↗	FY 2014 Jun 30, 2015 10-K ↗	FY 2013 Jun 30, 2014 10-K ↗	FY 2012 Aug 31, 2012 10-K ↗	FY 2011 Aug 31, 2011 10-K ↗
Return on Invested Capital (%)	-54.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-186.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-96.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-90.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-47.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-45.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-132.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	99.1% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-390.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-181.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-153.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	29.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	-83.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-62.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-183.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-106.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-105.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-56.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-51.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-12.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-124.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-226.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-254.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-158.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-70.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-26.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-65.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-66.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-542%)	-225.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1601%)	-115.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-872%)	-111.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-846%)	-60.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-503%)	-56.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-475%)	-13.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-186%)	-227.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1616%)	162.5% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+984%)	—	-42.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-382%)	-236.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1674%)	110.7% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+638%)	-106.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-807%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Jun 30, 2019 10-K ↗	FY 2017 Jun 30, 2018 10-K ↗	FY 2016 Jun 30, 2017 10-K ↗	FY 2015 Jun 30, 2016 10-K ↗	FY 2014 Jun 30, 2015 10-K ↗	FY 2013 Jun 30, 2014 10-K ↗	FY 2012 Aug 31, 2012 10-K ↗	FY 2011 Aug 31, 2011 10-K ↗
Interest Coverage (x)	—	—	—	—	—	-25192.00x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-1672.49x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-2145.28x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-2703.19x Weak Weak Operating income divided by interest expense Optimal: > 5x	-2723.06x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	-30.75x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-3.50M	$-3.86M	$-4.09M	$-5.40M	$-44.44M	$-2.50M	$-36.28M	$-2.43M	$-2.24M	$-1.71M	$-8.50M	$-22.47M	$-3.52M	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Jun 30, 2019 10-K ↗	FY 2017 Jun 30, 2018 10-K ↗	FY 2016 Jun 30, 2017 10-K ↗	FY 2015 Jun 30, 2016 10-K ↗	FY 2014 Jun 30, 2015 10-K ↗	FY 2013 Jun 30, 2014 10-K ↗	FY 2012 Aug 31, 2012 10-K ↗	FY 2011 Aug 31, 2011 10-K ↗
Basic EPS, GAAP (USD)	$-1.45	$-2.65	$-3.28	$-5.30	$-7.16	—	—	—	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-1.16	$-1.72	$-1.72	$-3.50	$-5.23	—	—	—	—	—	—	—	—	—	—
Book Value per Share (USD)	$1.18	$1.18	$2.84	$4.67	$7.51	$6.46	$8.00	$0.78	$-0.44	$0.12	$0.59	$0.82	$-2.23	—	—
Tangible Book Value per Share (USD)	$1.18	$1.18	$2.84	$4.67	$7.51	$6.46	$8.00	$0.78	$-0.44	$0.12	$0.59	$0.82	$-2.23	—	—
Basic Weighted Avg Shares (shares)	39.48M	30.16M	30.10M	29.63M	17.55M	—	—	—	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Jun 30, 2019 10-K ↗	FY 2017 Jun 30, 2018 10-K ↗	FY 2016 Jun 30, 2017 10-K ↗	FY 2015 Jun 30, 2016 10-K ↗	FY 2014 Jun 30, 2015 10-K ↗	FY 2013 Jun 30, 2014 10-K ↗	FY 2012 Aug 31, 2012 10-K ↗	FY 2011 Aug 31, 2011 10-K ↗
Working Capital (USD)	$87.55M	$35.50M	$85.31M	$140.40M	$208.24M	$105.47M	$115.48M	$7.38M	$-3.17M	$1.10M	$6.24M	$8.39M	$-1.03M	$11.36K	—
Total Equity (USD)	$86.51M	$35.52M	$85.36M	$140.44M	$208.26M	$105.58M	$115.68M	$7.61M	$-5.51M	$1.46M	$7.04M	$8.81M	$-17.95M	$11.36K	$9.91K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Jun 30, 2019 10-K ↗	FY 2017 Jun 30, 2018 10-K ↗	FY 2016 Jun 30, 2017 10-K ↗	FY 2015 Jun 30, 2016 10-K ↗	FY 2014 Jun 30, 2015 10-K ↗	FY 2013 Jun 30, 2014 10-K ↗	FY 2012 Aug 31, 2012 10-K ↗	FY 2011 Aug 31, 2011 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	—	—	—	—	—	—	—	—	—	$7.94K	—
Depreciation Expense (USD)	—	—	—	—	$1.26K	$3.75K	$4.36K	$4.87K	$2.63K	$85.27K	$54.82K	$9.26K	$373.00	—	—
Net Income, GAAP (USD)	$-57.39M	$-79.98M	$-98.79M	$-157.04M	$-125.75M	$-59.46M	$-15.01M	$-17.32M	$-8.96M	$-6.29M	$-2.97M	$-20.80M	$-19.87M	$-12.05K	—
Operating Cash Flow (USD)	$-45.79M	$-51.76M	$-51.66M	$-103.80M	$-91.87M	$-27.81M	$-12.09M	$-10.50M	$-6.00M	$-6.47M	$-13.14M	$-16.23M	$-2.24M	$-7.57K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 59 quarters

RELMADA THERAPEUTICS, INC.

Analytical Summary

15-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare RLMD with peers